Skip to main content

ORIGINAL RESEARCH article

Front. Cardiovasc. Med.
Sec. General Cardiovascular Medicine
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1476976

Vericiguat Combined with "New Quadruple" Therapy Enhances Cardiac Function and Life Quality in Patients with Heart Failure: A single-center prospective study

Provisionally accepted
Di Zhao Di Zhao Yanjuan Zhang Yanjuan Zhang Yonghong Yong Yonghong Yong Lian-Sheng Wang Lian-Sheng Wang Jiabao Liu Jiabao Liu *
  • First Affiliated Hospital, Nanjing Medical University, Nanjing, China

The final, formatted version of the article will be published soon.

    Objective: To investigate the therapeutic effect of vericiguat combined with "new quadruple" drugs on patients with heart failure. Methods: From December 1, 2022 to February 1, 2024, 103 patients with heart failure were consecutively enrolled from the cardiology clinic or ward of the First Affiliated Hospital of Nanjing Medical University. Before enrollment, the patients' LVEF, LVEDD, NT-proBNP, liver and kidney function electrolytes, and MLHFQ and other indicators were measured. Patients diagnosed with HFrEF and with HFmrEF were treated with vericiguat combined with "ARNI, BB, MRA, SGLT2i" therapy. Patients diagnosed with HFpEF were treated with vericiguat combined with "ARNI, BB, SGLT2i" therapy. The above indicators were rechecked after one month of treatment. Results: For all patients, comparison after treatment: LVEF (38.1±8.5% vs. 43.1±8.5%, p<0.01), LVEDD (60.5±8.1mm vs. 58.2±7.3mm, p<0.01), NT-proBNP (4567.8±5163.9ng/L vs. 1895.6±2702.1ng/L, p<0.01), MLHFQ (45.72±11.09±11.09 vs. 32.29±9.41, p<0.01). Further subgroup analysis showed that Vericiguat combined with "ARNI, BB, SGLT2i or MRA" improved the LVEF and reduced NT-proBNP levels in patients with HFrEF, HFmrEF or HFpEF. and improved patients' quality of life scores. The intergroup comparison showed the therapeutic effect of the combination was equivalent in HF caused by MI, DCM or VHD. Conclusion: Vericiguat combined with the "new quadruple" therapy has a significant therapeutic effect on patients with heart failure caused by MI, DCM or VHD.

    Keywords: Heart Failure, vericiguat, Myocardial Infarction, dilated cardiomyopathy, Valvular Heart Disease

    Received: 06 Aug 2024; Accepted: 27 Sep 2024.

    Copyright: © 2024 Zhao, Zhang, Yong, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jiabao Liu, First Affiliated Hospital, Nanjing Medical University, Nanjing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.